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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a betacoronavirus that causes 
coronavirus disease (COVID-19), a respiratory infec-
tion with systemic involvement and an estimated 1% 
death rate (1). COVID-19 was first documented in 
Wuhan, China (2), at the end of 2019. The outbreak 
quickly transformed into a pandemic. Countries have 
tried to manage the pandemic by implementing dif-
ferent strategic interventions with varying levels of 
success (3). Experts agree that diagnostic tests, and 
the subsequent interventions they generate, are es-
sential to controlling SARS-CoV-2 transmission.
Reverse transcription PCR (RT-PCR) relies on 
RNA sequencing rather than viral proteins, enabling 
researchers to develop assays shortly after the viral 
sequence is identified. Because of this advantage, RT-
PCR quickly became a common testing method for 
COVID-19 (4). However, the urgent global scale-up 
of nucleic acid amplification testing, including PCR, 
exposed supply chain vulnerabilities, such as short-
ages of swabs and reagents. Diagnostic tests remain 
unaffordable in many developing countries, limiting 
national containment strategies.
Serologic assays for viral infections can con-
tribute to vaccine development, diagnostic deploy-
ment, and prescription of new therapeutics. They 
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We investigated the dynamics of seroconversion in severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in-
fection. During March 29–May 22, 2020, we collected serum 
samples and associated clinical data from 177 persons in 
London, UK, who had SARS-CoV-2 infection. We measured 
IgG against SARS-CoV-2 and compared antibody levels with 
patient outcomes, demographic information, and laboratory 
characteristics. We found that 2.0%–8.5% of persons did not 
seroconvert 3–6 weeks after infection. Persons who sero-
converted were older, were more likely to have concurrent 
conditions, and had higher levels of inflammatory markers. 
Non-White persons had higher antibody concentrations than 
those who identified as White; these concentrations did not 
decline during follow-up. Serologic assay results correlated 
with disease outcome, race, and other risk factors for se-
vere SARS-CoV-2 infection. Serologic assays can be used 
in surveillance to clarify the duration and protective nature of 
humoral responses to SARS-CoV-2 infection.
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might also offer insight into pathophysiological as-
pects of COVID-19. We used ELISA (Mologic Ltd., 
https://mologic.co.uk) for COVID-19 to character-
ize the serologic response in SARS-CoV-2 infection. 
These tests were designed for affordability and ac-
curacy, enabling access and manufacture in low- 
and middle-income countries. We used these tests 
on serum samples from persons with confirmed 
SARS-CoV-2 infection in London, UK, to identify 




Development of the SARS-CoV-2 IgG ELISA is 
available elsewhere (E.R. Adams, unpub. data, 
https://www.medrxiv.org/content/10.1101/2020.
04.29.20082099v1). We analyzed antibody dynam-
ics using anonymized excess diagnostic material 
from patients with PCR-confirmed SARS-CoV-2 in-
fection. The study was sponsored by St. George’s 
Hospital National Health Services Foundation 
Trust (London) and has Institutional Review Board 
ethics approval (Development and Assessment of 
Rapid Testing for SARS-CoV-2 outbreak study; In-
tegrated Research Application System project ID: 
282104; Research Ethics Committee reference: 20/
SC/0171). The trial is registered at ClinicalTrials.
gov under NCT04351646.
Reference RT-PCR
Staff at St. George’s Hospital used Sigma Virocult 
(MWE, https://www.mwe.co.uk) to collect nose and 
throat swab samples from patients with SARS-CoV-2 
infection; we prepared the samples with RNA extrac-
tion kits (Roche Molecular Systems Inc., https://www.
lifescience.roche.com). We confirmed infection with 
the RealStar SARS-CoV-2 RT-PCR Kit selective for the 
S and E genes (Altona Diagnostics GmbH, https://
www.altona-diagnostics.com) or cobas SARS-CoV-2 
Test selective for the E gene and open reading frames 
1ab (Roche Molecular Systems, Inc.).
Clinical Samples
South West London Pathology (London) provides 
microbial diagnostic testing for the region, including 
St. George’s Hospital, a tertiary teaching hospital. 
We obtained excess diagnostic material from South 
West London Pathology in the form of serum sam-
ples from patients with RT-PCR confirmed SARS-
CoV-2 infection. The serum samples were anony-
mized and stored at 4°C for <2 weeks. Patients were 
sampled longitudinally to assess antibody dynamics; 
the data comprised >30 samples per day. If samples 
became unavailable from 1 patient (i.e., the patient 
was discharged or died), we added a new patient to 
the cohort. Excess diagnostic material was collected 
from 177 persons during March 29–May 22, 2020. 
The study population consisted of 9.9% (177/1,785) 
of persons (patients and staff) who tested positive 
for SARS-CoV-2 infection at South West London Pa-
thology during this period.
Participants and Clinical Data
We obtained data from patients’ electronic medi-
cal records. We coded outcomes (as of May 22) as 
hospital admission, intensive care unit stay, death, 
or discharge. We recorded the length of hospi-
tal stay of patients who were discharged or died. 
We considered peaks of inflammatory markers 
(e.g., C-reactive protein [CRP]) to be the highest 
values recorded from 5 days before the first posi-
tive swab sample through the end of the study. 
We obtained blood values at the time of diagnosis 
(within 3 days after the first positive swab sample 
was taken).
ELISA for SARS-CoV-2 IgG
We used the COVID-19 IgG ELISA developed by Mologic 
Ltd. and manufactured by Omega (Omega Diagnos-
tics Group PLC, http://www.omega-diagnostics.com), 
according to the manufacturer’s instructions (Appendix 
1, https://wwwnc.cdc.gov/EID/article/27/1/20-3074-
App1.pdf). The assay contained the spike and nucleo-
protein antigens of SARS-CoV-2. Between plate coeffi-
cients of variation were 21.0% (lower cutoff) and 16.5% 
(positive control; n = 16). Higher ambient temperatures 
in the laboratory resulted in higher optical density 
readings (Appendix 2, https://wwwnc.cdc.gov/EID/ 
article/27/1/20-3074- App2.xlsx).
Statistical Analyses
We cross-checked and normalized raw ELISA data to 
enable comparison (Appendix 1; Figure 1). We also 
resolved manual handling errors (Appendix 1). We 
applied 2-tailed parametric and nonparametric tests 
as appropriate, using PRISM version 8.0 (https://
www.graphpad.com) for data analysis and display. 
We conducted a 1-way analysis of variance to com-
pare the effects of race and demographic information 
on patient outcomes. We used multivariate linear re-
gression to determine the relationship between mean 
normalized optical density (NOD) and age, sex, peak 
CRP, number of concurrent conditions, respiratory 
symptoms, and race.
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Patient and Public Involvement
We acknowledge the importance of patient and pub-
lic involvement in clinical studies. However, because 
of the rapid progression of COVID-19 and the chal-
lenges of lockdown in the United Kingdom, we did 
not have sufficient time to involve patients and mem-
bers of the public in the development, implementa-
tion, or interpretation of this study.
Results
We studied 177 patients who provided 645 distinct 
excess diagnostic material samples (Table 1). Pa-
tients were from diverse ethnic backgrounds (34% 
White, 35% non-White, 31% unreported; Appen-
dix 1 Table 1), the a median age was 64 years (in-
terquartile range [IQR] 52–77 years). Fifty-seven 
percent were male, and 73% had >1 concurrent 
condition. Nineteen percent were asymptomatic and 
did not report respiratory symptoms at admission; 
these patients tested positive for SARS-CoV-2 infec-
tion while receiving treatment for other conditions. 
Among the 143 symptomatic patients, the median 
time from symptom onset to testing was 6 days (IQR 
3–9 days). Of the 177 patients, 166 (94%) were hos-
pitalized, 7 (4%) were staff, and 4 (2%) were outpa-
tients. Of the hospitalized patients, 44 (27%) died 
(median time to death was 19.1 days [IQR 14.8–24.8 
days]), 108 (65%) were discharged (median length 
of stay was 19.3 days [IQR 10.6–31.1 days]), and 14 
(8%) remained hospitalized at the end of the study. 
Sixty-three (38%) patients were admitted to inten-
sive care during the study.
We normalized optical densities proportional to 
levels of SARS-CoV-2 IgG (Figure 1, panel A). Of the 
177 patients, 149 (84% [95% CI 78%–89%]) had already 
seroconverted at the time of the first serologic test, 13 
(7.3% [95% CI 4.3%–12.1%]) seroconverted after the 
first serologic test, and 15 (8.5 % [95% CI 5.2–13.5%]) 
did not seroconvert during the entire follow-up peri-
od (Appendix 1 Figure 2). Of the 15 patients who did 
not seroconvert, samples from beyond day 20 were 
available for 4 patients (26%); we did not detect IgG in 
these samples. This finding suggests that 2.0%–8.5% 
of patients might not develop detectable IgG against 
SARS-CoV-2.
We plotted NODs by time after a patient’s first 
positive swab sample (Figure 1, panel B) and after 
symptom onset (Figure 1, panel C). NODs plateaued 
≈12 days after PCR and ≈19 days after symptom on-
set; this time difference is consistent with the medi-
an time of 6 days between symptom onset and PCR. 
After seroconversion, mean NODs remained stable 
over the course of the study (up to ≈60 days after 
symptom onset).
We assessed whether the rate of seroconversion 
was associated with patient age (<70 or >70 years), sex, 
or respiratory symptoms. None of these variables were 
discernably associated with seroconversion rates (Ap-
pendix 1 Figure 3, panels A–C). NOD IgG levels were 
not associated with sex or the presence of respiratory 
symptoms. (Appendix 1 Figure 4, panels A, B).
Patients of non-White race had higher mean 
NODs than those of White race (1.06 vs. 0.85; F = 1.61, 
df = 119; p = 0.04 by unpaired Student t-test) (Appen-
dix 1 Figure 4, panel C). No other differences were 
associated with race. We used a multivariate analy-
sis to identify variables independently associated 
with NODs; the mean NOD was associated only with 
age, peak CRP, and race. Although age, sex, peak 
CRP, number of concurrent conditions, respiratory 
 
Table 1. Demographic and clinical characteristics of patients with 
severe acute respiratory syndrome coronavirus 2 infection, 
United Kingdom, 2020* 
Characteristics Results 
Median age, y (IQR) 64 (52–77) 
Median body mass index (IQR)† 25.4 (21.9–30.5) 
Sex  
 M 100 (56.5) 
 F 77 (43.5) 
Race  
 White 60 (33.9) 
 Non-White 61 (34.5) 
 Other/not known 56 (31.6) 
Concurrent conditions  
 0 47 (26.6) 
 1 52 (29.4) 
 2 50 (28.2) 
 >3 28 (15.8) 
Symptoms  
 Symptomatic 143 (80.8) 
 Median days from symptom onset to  
 PCR (IQR) 
6 (3–9) 
Diagnostic site  
 Emergency department 90 (50.8) 
 Outpatient 12 (6.8) 
 Ward 54 (30.5) 
 Intensive care unit 14 (7.9) 
 Occupational health staff 7 (4.0) 
Treatment location  
 Occupational health staff 7 (4.0) 
 Outpatient 4 (2.3) 
 Hospital 166 (93.8) 
Admitted to intensive care unit 63 (38.0) 
Outcomes  
    Never hospitalized 11 (6.2) 
 Discharged 108 (61.0) 
  Median length of stay, d (IQR) 19.3 (10.6–31.1) 
 Death 44 (24.9) 
  Median length of stay, d (IQR) 19.1 (14.8–24.8) 
 Death and/or ICU admission 80 (45.2) 
 Still in hospital‡ 14 (7.9) 
*Values are no. (%) except as indicated. ICU, intensive care unit; IQR, 
interquartile range. 
†Height unavailable for 13 patients. 
‡As of May 22, 2020. 
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symptoms, and race were associated with patient 
outcome in the univariate analysis, only peak CRP 
was associated with poor outcome in the multivariate 
analysis (Appendix 1).
Persons who seroconverted were older than 
those who did not (median age 65.5 vs. 41.0 years; 
p<0.01 by Mann-Whitney test) and more likely to 
have >1 concurrent condition (124/130 vs. 38/47; 
p<0.01 by Fisher exact test). History of hypertension 
was associated with a higher probability of serocon-
version (74/75 persons with hypertension vs. 88/102 
persons without hypertension; p<0.01 by Fisher exact 
test). Body mass index was higher among the group 
who seroconverted (25.7 vs. 21.2; p = 0.03 by Mann- 
Whitney test).
Unlike other markers of inflammation, CRP is rou-
tinely measured in patients with COVID-19. Rising 
CRP levels are indicators of a poor prognosis (if other 
causes are excluded), and are associated with cytokine 
release syndrome (5; Y. Woo, unpub. data, https://osf.
io/mxsvw). CRP levels were significantly higher in pa-
tients with respiratory symptoms at diagnosis than in 
those without symptoms (Figure 2, panel A). Patients 
who died or required intensive care during the study 
period had higher CRP levels than patients who did 
not die or require intensive care (Figure 2, panel B). Pa-
tients who did not seroconvert had lower CRP levels 
than those who did (Figure 2, panel C). Peak CRP lev-
els had more pronounced associations with outcomes 
and seroconversion than did CRP levels at the time of 
the first positive swab sample result (Figure 2, panels 
D–F). CRP levels peaked a median of 12 days (IQR 8–17 
days) after symptom onset and 4 days (IQR 1–11 days) 
after the first positive PCR result. Other inflammatory 
markers, such as peak D-dimer, fibrinogen, and ferri-
tin, were also higher in patients with respiratory symp-
toms at diagnosis. However, these data were available 
for fewer patients (Table 2; Appendix 1 Table 3).
Discussion
Our results illustrate serologic responses over the 
course of SARS-CoV-2 infection. Serologic tests can 
enhance diagnostic capability, especially during later 
infection (4,6,7), when viral loads might decrease. Se-
rologic testing might also inform surveillance, sero-
epidemiologic studies, and contact tracing. Our study 
shows that a substantial proportion of COVID-19 pa-
tients require 3–6 weeks to generate antibodies. Fur-
thermore, 2.0%–8.5% of patients do not have detect-
able antibodies within 60 days after infection. Most 
research on antibody dynamics came from China 
during the early stages of the pandemic (4,6,8). Here, 
we describe variables that influence IgG dynamics in 
SARS-CoV-2 infections in diverse populations.
The performance metrics of this ELISA (Figure 1; 
Appendix 2) are comparable to other validated assays. 
This first-generation ELISA might confirm infection in 
patients without a virologic diagnosis. We applied this 
test to study an ethnically and clinically diverse popula-
tion. In most persons who seroconverted, the conversion 
Figure 1. Antibody dynamics in patients with severe acute 
respiratory syndrome coronavirus 2, United Kingdom, 2020. 
A) NOD by days after first positive PCR result. Blue indicates 
seroconverting patients; red indicates nonseroconverting patients. 
B) Mean (± SEM) NODs (>3 samples per time point; n = 48) by 
days after first positive PCR result for those who seroconverted. A 
4-parameter sigmoidal unconstrained model is shown (r2 = 0.45). 
C) Mean (± SEM) NODs (>3 per time point; n = 45) by days after 
symptom onset for patients who seroconverted. A 4-parameter 
sigmoidal unconstrained model is shown (r2 = 0.63). NOD, 
normalized optical density.
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 1, January 2021 89
Seroconversion and Pathophysiology in SARS-CoV-2
was relatively rapid; NODs remained stable for weeks 
after infection (Figure 1). The probability of seroconver-
sion was associated with increased age and concurrent 
conditions such as hypertension and increased body 
mass index. Higher NODs were associated with non-
White race, admission to hospital, and higher peaks for 
inflammatory markers, such as CRP. Higher antibody 
titers are associated with clinical severity (i.e., death or 
admission to intensive care during study) in our cohort, 
in agreement with findings from other studies (4).
CRP is a sensitive marker of elevated proinflam-
matory cytokines, including interleukin 6. These 
cytokines might play a central role in cytokine re-
lease syndrome, which is associated with increased 
risk for death (Y. Woo, unpub. data, https://osf.io/
mxsvw). Interventions such as tocilizumab, an in-
terleukin-6 receptor antibody, interrupt the proin-
flammatory cascade. Such interventions might limit 
disease progression and reduce risk for death (9; 
E. Baker, unpub. data, https://osf.io/d2nh8); they 
are being studied in several randomized clinical tri-
als. In our study, a small proportion of patients did 
not seroconvert within 20 days after testing positive 
for SARS-CoV-2 infection. Several mechanisms might 
explain this finding. First, these patients might never 
seroconvert. Second, their immune responses might 
be confined to other antigens or mediated through 
T cells. Another probable explanation is that some 
relatively mild infections might be restricted to the 
mucosal cells of the respiratory tract, where antibody 
responses are dominated by the secretory immune 
system. In this scenario, the systemic immune system 
might produce little or no IgG.
The association of higher NODs with elevated 
CRPs could indicate several potential pathways. For 
example, antibody responses might be closely related 
to cytokine response syndrome, which in turn is as-
sociated with more severe disease and death. Alter-
natively, elevated CRPs might indicate a more pro-
nounced innate immune response in persons already 
Figure 2. Relationships between CRP levels, symptoms, outcomes, and NODs of patients with severe acute respiratory syndrome 
coronavirus 2, United Kingdom, 2020. A–C) CRPs at diagnosis for A) 113 symptomatic (open circles) and 21 asymptomatic (closed 
circles) patients (CRP 97 vs. 56; p<0.01); B) 62 patients admitted to intensive care and/or who died (open circles) and 72 who were not 
admitted to intensive care (closed circles) (CRP 107 vs. 75.5; p = 0.01); C) 123 patients who seroconverted (open circles) and 11 who 
did not (closed circles) (CRP 93 vs. 28; p = 0.04). D–F) Peak CRPs corresponding to the populations in A–C: D) 255 (n = 142) vs. 104 (n 
= 34) (p<0.01); E) 322 (n = 80) vs. 137.5 (n = 96) (p<0.01); F) 224 (n = 161) vs. 101 (n = 15) (p = 0.03). Statistical significance calculated 
using Mann-Whitney test for CRPs (mg/L). CRP, C-reactive protein; NOD, normalized optical density.
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at risk for severe disease and death. This heightened 
innate response might be associated with a higher 
viral load (potentially caused by enhanced viral rep-
lication mechanisms) and genetic interactions that 
influence innate inflammatory pathways. Therefore, 
a higher viral load might lead to higher NODs for an-
tibodies in the acquired immune response pathways. 
Small trials on the potential therapeutic benefits of in-
terventions using passive antibody transfer (10) sug-
gest that the heightened innate response hypothesis 
is more probable (11). Higher antibody responses are 
also associated with higher doses of a nonreplicating 
Ad5-vectored vaccine for SARS-CoV-2 (12).
Limitations of PCR include difficulties with sam-
pling; different sample types and techniques yield 
varying results. Furthermore, PCR demonstrates di-
minishing diagnostic yield for COVID-19 as respira-
tory viral loads fall and symptoms subside (8,13). It 
might also produce false positives caused by lingering 
viral nucleic acid, which is not infective yet can persist 
for weeks after infection. Contamination could also 
occur during sample handling; because PCR requires 
amplification steps, this assay has heightened risk for 
contamination. Serologic testing, and the ability to de-
tect viral antigens, may increase diagnostic accuracy 
for COVID-19. Our findings support early studies 
suggesting that physicians should consider these di-
agnostic modalities in conjunction, especially when a 
patient has negative PCR results but has symptoms of 
COVID-19 (6). Many COVID-19 patients experience a 
delay in care, a trend that emphasizes the importance 
of containment strategies that encourage isolation.
One limitation of our study is that it is based mainly 
on hospitalized patients, of whom 1 in 5 did not have 
COVID-19 symptoms. Further studies should docu-
ment antibody dynamics of patients with less severe 
infections, such as healthcare workers (14), and pa-
tients with low viral loads at the time of consultation. 
Our findings will complement the large cross-sectional 
and longitudinal serologic surveys, especially as high-
quality tests become more widely available. NODs were 
within a limited dynamic range (we could not conduct 
dilution studies because of small sample volumes) but 
nevertheless associated with clinically relevant features 
of COVID-19. Prospective studies are assessing the re-
lationships between viral loads and serologic responses 
in patients. Regular and long-term serologic assays will 
be essential to monitoring the duration of the humoral 
response and its protective role against SARS-CoV-2.
When interpreting serologic assays of COVID-19 
patients, physicians should consider factors that can 
influence the probability of seroconversion. Our 
study elucidates some of these factors. We found 
that less severe infections and younger age were as-
sociated with reduced probability of seroconversion. 
Risk factors for more severe disease, such as non-
White race, increased age, and hypertension, are also 
associated with increased inflammatory responses, 
higher normalized antibody titers, and probability 
of seroconversion.
This article was preprinted at https://www.medrxiv.org/
content/10.1101/2020.06.07.20124636v2.
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Table 2. Selected laboratory values of patients with severe acute respiratory syndrome coronavirus 2 infection, United Kingdom, 
2020* 
Variable (reference range) 
At diagnosis  Peak 
No. Median (IQR) No. Median (IQR) 
C-reactive protein (0–5 mg/L) 134 86 (52.5–164)  176 215.5 (103–334) 
Nadir lymphocytes count (1.1–4.0 × 109/L) 134 0.9 (0.6–1.4)  177 0.6 (0.4–0.8) 
Ferritin (30–400 μg/L) 42 1,084 (630–1,721)  89 1,335 (846–2,758) 
Fibrinogen (1.6–4.8 g/L) 133 5.5 (4.2–6.7)  166 7.0 (5.5–9.15) 
D-dimer (21–300 ng/mL) 64 704 (395–1,079)  111 1,905 (498–4,095) 
Lactate dehydrogenase (0–250 U/L) 47 475 (280–597.5)  87 490 (344.5–704) 
*IQR, interquartile range. 
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Serum samples were diluted 1 in 200 in dilution solution (10 mM Tris buffered saline, pH 
7.2 with antimicrobial agents) and 100 µL loaded per well, in duplicate (although an initial plate 
was loaded in triplicate), onto a 96-well microtiter plate coated with the spike (S) and 
nucleoprotein (NP) antigens of SARS-CoV-2 (an early generation assay used NP, S1 and S2 
antigens and the final version used only NP and S2 antigens, with S1 being removed). Six wells 
contained controls: negative (diluent solution), negative cutoff (purified human IgG in 10 mM 
Tris buffered saline) and positive (purified human IgG in 10 mM Tris buffered saline), in 
duplicates. The plate was incubated at room temperature for 30 min before 3 washes with wash 
buffer (10 mM Tris-buffered saline with detergent, pH 7.2). Following the wash step, 100 µL of 
conjugate solution (IgG against humans, conjugated to horseradish peroxidase with protein 
stabilization and antimicrobial agents) was added to every well and the plate incubated for 30 
min at room temperature before 4 washes with wash buffer. Indicator/substrate solution 
(3,3′,5,5′-tetramethylbenzidine, TMB, with H2O2; 100 µL) was added to every well and the plate 
incubated at room temperature for 10 min before addition of 100 µL stop solution (0.25 M 
H2SO4) per well. The plate was read with a spectrometer at 450 nm within 10 min of stop 
solution addition. Wells with an optical density of 10% greater than the negative cutoff value 
were regarded as positive for antibodies to SARS-CoV-2 antigen. 
Normalization 
For each plate the mean cutoff OD value plus 10% (lower cutoff) was subtracted from 
each mean patient sample OD value (thus samples with negative values were considered 
 
Page 2 of 8 
negative and samples with positive values were considered positive for SARS-CoV-2 
antibodies). To normalize, the resulting value was divided by the mean positive control OD 
value. Any assayed duplicates (serum samples taken from the same patient on the same day) 
were removed from further analysis. 
Resolving Inconsistencies 
Inconsistent data points (n = 3) were identified (e.g., a data point that suggested a 
seropositive patient subsequently lost their antibody response). In these cases: samples were 
rerun, including sequential samples from the same patient from either side of the timepoint; 
alkaline phosphatase results from that sample were checked; and sample aliquots were resourced 
from stocks in South West London Pathology laboratories. 
Results 
Normalized ELISA Values 
Normalized OD values for ELISA results are presented in Appendix Figure 1. 
Analysis 
A 1-way analysis of variance was conducted to compare the effect of race 
(white/nonwhite/unknown) on demographics and severity indices in patients. Results showed 
that antibody levels (mean NOD) across the 3 groups were unequal, F (2,174) = 3.46, p = 0.03 
and post hoc comparisons using Tukey’s test showed that antibody levels in whites were 
significantly different from nonwhites. There was no observed significant effect of race on other 
measured severity indices and demographics (Appendix Table 3). 
Multiple Linear Regression (Independent Variable: Mean NOD) 
Multiple linear regression was performed to determine the relationship between mean 
NOD and age, sex, peak CRP levels, number of concurrent conditions, presence or absence of 
respiratory symptoms, and race. Upon examination of regression β coefficients and associated t-
statistic p values, there was a significant association found between higher age, higher peak CRP 
levels, nonwhite race, and higher NOD values. The p value of the F-statistic is 8.6 × 10–5 with an 
adjusted R-squared (R2) of 0.10 (10% of the variance in mean NOD levels can be predicted by 
the 3 variables). 
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Our final model equation can be written as follows: 
mean NOD = 0.38 + 0.005 × age + 0.001 × peak CRP level – 0.018 × race. 
Race was coded as a dummy quantitative variable (0 = nonwhite race, 1 = white race). 
Logistic Regression Model (Independent Variable: Seroconversion) 
Logistic regression was performed to determine the relationship between seroconversion 
and age, sex, peak CRP levels, number of concurrent conditions, presence or absence of 
respiratory symptoms, and race. A significant association was found between higher age, higher 
peak CRP levels and seroconversion (p = 0.001 and p = 0.035 respectively). 
Our final model equation can be written as follows: 
Log odds of seroconversion = −1.37 + 0.051 × age + 0.004 × peak CRP level 
Logistic Regression Model (Independent Variable: Severity/outcome) 
Logistic regression was performed to determine the relationship between poor outcome 
(death and or ICU admission) and age, gender, peak CRP levels, number of concurrent 
conditions, presence or absence of respiratory symptoms, and race. A significant association was 
found between only higher peak CRP levels and poor outcome (p = 1.1 × 10–8). 
Our final model equation can be written as follows: 
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Appendix 1 Table 1. Expanded characteristics of patients with severe acute respiratory syndrome, United Kingdom, 2020 
Characteristic No. patients (%) 
Race*  
 White 60 (33.9) 
  British 38 (21.5) 
  Irish 1 (0.6) 
  Other 21 (11.9) 
 Nonwhite 61 (34.5) 
  Black or black British  
   African 13 (7.3) 
   Caribbean 9 (5.1) 
   Other 5 (2.8) 
  Asian or Asian British  
   Bangladeshi 1 (0.6) 
   Indian 6 (3.4) 
   Pakistani 2 (1.1) 
   Other 22 (12.4) 
  Mixed 3 (1.7) 
 Other/not known 56 (31.6) 
  Other  33 (18.6) 
  Not stated 23 (13.0) 
Concurrent conditions  
 None 47 (26.6) 
 Diabetes mellitus 52 (29.4) 
 Hypertension 75 (42.4) 
 Obesity (body mass index >30)† 44 (26.8) 
 Chronic kidney disease 27 (15.3) 
  Without dialysis 15 (8.5) 
  Hemodialysis 10 (5.6) 
  Renal transplant 2 (1.1) 
 Cancer 18 (10.2) 
 Asthma 21 (11.9) 
 Chronic obstructive pulmonary disease 6 (3.4) 
*Race data are routinely collected by the National Health Service and categorised based on the 2001 UK Census classification. 
†Height data unavailable for 13 patients. 
 
 
Appendix 1 Table 2. Examination of demographics and severity indices in patients with severe acute respiratory syndrome 2, 
United Kingdom, 2020 
Variable F statistic p value 
Mean normalized optical density 3.46 0.03 
Age 0.70 0.50 
Gender 0.33 0.72 
Body mass index 0.08 0.93 
Concurrent conditions 1.26 0.29 
Respiratory symptoms 0.72 0.49 
Length of stay, d 1.38 0.26 
Poor outcome (death and or intensive 
care unit) 
0.99 0.38 
Peak C-reactive protein levels 1.03 0.36 
 
 
Appendix 1 Table 3. Laboratory values at diagnosis from symptomatic and asymptomatic patients with severe acute respiratory 
syndrome coronavirus 2, United Kingdom, 2020. 
Test (reference range) 
Median (IQR), n = 177 
p value* Symptomatic Asymptomatic 
C-reactive protein (0–5 mg/L) 97 (57.5–194), n = 113 56 (5.5–100.5), n = 21 <0.01 
Nadir lymphocytes count (1.1–4.0 × 109/L) 0.9 (0.6–1.4), n = 113 1.0 (0.55–1.3), n = 21 0.76 
Ferritin (30–400 µg/L) 1,134 (659.8–1,829), n = 40 222 (121–323), n = 2 0.04 
Fibrinogen (1.6–4.8 g/L) 5.5 (4.3–6.7), n = 116 4.3 (2.9–6.25), n = 17 0.05 
D-dimer (21–300 ng/mL) 705 (397–1,105), n = 59 703 (320–3,536), n = 5 0.91 
Lactate dehydrogenase (0–250 U/L) 497 (282.3–600.3), n = 44 225 (210–703), n = 3 0.44 




Page 5 of 8 
Appendix 1 Table 4. Peak laboratory values in symptomatic and asymptomatic patients with severe acute respiratory syndrome 
coronavirus 2, United Kingdom, 2020 
Test (reference range) 
Peak value 
Median (IQR) 
p value* Symptomatic Asymptomatic 
C-reactive protein (0–5 mg/L) 255 (134.5–344.5), n = 142 104 (70.8–190.8), n = 34 <0.01 
Nadir lymphocytes count (1.1–4.0 × 109/L) 0.5 (0.4–0.8), n = 143 0.65 (0.375–0.9), n = 34 0.46 
Ferritin (30–400 µg/L) 1,363 (1,019–2,848), n = 79 624 (338–1,497), n = 10 0.02 
Fibrinogen (1.6–4.8 g/L) 7.6 (5.6–9.5), n = 135 1.18 (1.18–1.18), n = 2 <0.01 
D-dimer (21–300 ng/mL) 2,534 (693.8–5,754), n = 96 460 (293–1,726), n = 15 <0.01 
Lactate dehydrogenase (0–250 U/L) 534 (363–707.5), n = 77 401 (202.5–740.5), n = 10 0.24 




Appendix 1 Figure 1. Normalization of raw ELISA values of patients with severe acute respiratory 
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Appendix 1 Figure 2. NOD values by days after first positive PCR result for patients with severe acute 
respiratory syndrome 2 who had seroconverted at the time of first assay, United Kingdom, 2020. NOD, 
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Appendix 1 Figure 3. Cumulative frequency plots for seroconversion of patients with severe acute 
respiratory syndrome coronavirus 2, United Kingdom, 2020. Probability of seroconversion is described in 
days after first positive PCR positive result. A) Patients with (filled squares) or without (filled circles) 
respiratory symptoms. Symbols indicate the last available seronegative sample for a patient subsequently 
right censored (i.e, no further data was available). B) Patients >70 years of age (filled squares) or <70 
years of age (filled circles). Symbols indicate the last available seronegative sample for a patient 
subsequently right censored. C) Men (filled squares) or women (filled circles). Symbols indicate the last 
available seronegative sample for a patient subsequently right censored. 
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Appendix 1 Figure 4. NOD values compared by sex, symptoms, and race of patients with severe acute 
respiratory syndrome coronavirus 2, United Kingdom, 2020. A) Comparison of NOD values by sex (mean 
± 95% CI; not significantly different); B) Comparison of NOD values by symptoms (mean ± 95% CI; not 
significantly different); C) Comparison of NOD values by race (mean ± 95% CI; p = 0.04, F = 1.61, 
df = 119; unpaired Student t-test between white and nonwhite). The third group is not known/other. NOD, 
normalized optical density.  
